Acura Pharmaceuticals (OTC: ACUR)
| Q3 2019 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | 0.000 | ||||||
| REV | 1.324M |
| Q2 2019 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.150 | ||||||
| REV | 92.000K | 46.000K | -46.000K |
| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
You can purchase shares of Acura Pharmaceuticals (OTCPK: ACUR) through any online brokerage.
There are no as such competitors for Acura Pharmaceuticals.
The latest price target for Acura Pharmaceuticals (OTCPK: ACUR) was reported by Roth Capital on Friday, March 11, 2016. The analyst firm set a price target for 6.00 expecting ACUR to rise to within 12 months (a possible 1032.08% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Acura Pharmaceuticals (OTCPK: ACUR) is $0.53 last updated May 17, 2022, 2:08 PM UTC.
There are no upcoming dividends for Acura Pharmaceuticals.
Acura Pharmaceuticals’s Q3 earnings are confirmed for Friday, February 28, 2020.
There is no upcoming split for Acura Pharmaceuticals.
Acura Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the OTCPK.